Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 3475 of 3499 entries
View as:

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

Phase: N/A Priority: Normal
NCT ID: NCT05886049 Org: User:
Start: 06/20/24 End: 12/31/27 Due: 12/31/28

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01174121 Org: User:
Start: 08/26/10 End: 12/27/29 Due: 12/27/30

Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)

Phase: N/A Priority: Normal
NCT ID: NCT02544022 Org: User:
Start: 11/13/15 End: 12/30/25 Due: 12/30/26

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Phase: N/A Priority: Normal
NCT ID: NCT06303167 Org: User:
Start: 01/08/16 End: 12/31/25 Due: 12/31/26

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02568553 Org: User:
Start: 11/15/16 End: 06/30/26 Due: 06/30/27

BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00023946 Org: User:
Start: 08/31/01 End: 11/30/09 Due: 11/30/10

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase: N/A Priority: Normal
NCT ID: NCT03155620 Org: User:
Start: 07/31/17 End: 05/09/26 Due: 05/09/27

A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder

Phase: N/A Priority: Normal
NCT ID: NCT00001381 Org: User:
Start: 03/31/94 End: 12/31/00 Due: 12/31/01

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05432804 Org: User:
Start: 03/20/23 End: 06/30/27 Due: 06/30/28

A Study to Evaluate Multicancer Detection (MCD) Tests and Their Impact on Participant Health and Cancer Screening, The Vanguard Study

Phase: N/A Priority: Normal
NCT ID: NCT06995898 Org: User:
Start: 11/19/25 End: 06/30/29 Due: 06/30/30

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Phase: N/A Priority: Normal
NCT ID: NCT06811116 Org: User:
Start: 02/10/26 End: 08/31/27 Due: 08/31/28

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

Phase: N/A Priority: Normal
NCT ID: NCT06514261 Org: User:
Start: 12/18/24 End: 09/16/26 Due: 09/16/27

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT01078441 Org: User:
Start: 09/30/10 End: 03/31/14 Due: 03/31/15

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00310089 Org: User:
Start: 01/31/06 End: 07/31/07 Due: 07/31/08

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00980460 Org: User:
Start: 09/14/09 End: 03/19/26 Due: 03/19/27

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01283035 Org: User:
Start: 04/30/11 End: 12/31/14 Due: 12/31/15

Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00324480 Org: User:
Start: 03/31/06 End: - Due: -

XK469R in Treating Patients With Refractory Hematologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00095797 Org: User:
Start: 10/31/04 End: - Due: -

A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04923178 Org: User:
Start: 10/24/22 End: 12/01/42 Due: 12/01/43

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01609790 Org: User:
Start: 06/04/12 End: 05/20/22 Due: 05/20/23

Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00052338 Org: User:
Start: 09/30/02 End: - Due: -

Docetaxel in Treating Children With Recurrent Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00002825 Org: User:
Start: 01/31/97 End: - Due: -

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02315430 Org: User:
Start: 04/01/15 End: 02/09/19 Due: 02/09/20

Cilengitide in Treating Patients With Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00089388 Org: User:
Start: 07/31/04 End: - Due: -

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02520791 Org: User:
Start: 09/13/16 End: 12/20/25 Due: 12/20/26